Horizon Therapeutics Public Ltd Executive Compensation (FY22)
HZNP · Executive and director compensation, fiscal 2022 only
Chief executive, fiscal 2022 ◇ Timothy Walbert | Median of the other named officers $7,174,543 5 officers, excluding the chief executive | Chief executive pay ratio ◇ To the median employee |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The Horizon Therapeutics Public Ltd brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Data as of November 5, 2026Latest filing (DEF 14A): June 30, 2023
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
175 figures on this page: 172 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is Horizon Therapeutics Public Ltd's chief executive and what were they paid?
Timothy Walbert, Chairman, President and Chief Executive Officer, received $20,103,869 in total compensation for fiscal 2022.
Which companies are in Horizon Therapeutics Public Ltd's peer group?
Companies named in the disclosed peer group include Alexion Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Biogen, Inc., BioMarin Pharmaceutical Inc. and Exelixis, Inc., among others.
What is Horizon Therapeutics Public Ltd's chief executive pay ratio?
The company reported a chief executive pay ratio of 76:1 for fiscal 2022, against median employee compensation of $264,751.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Timothy Walbert Chairman, President and Chief Executive Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Sean Clayton Executive Vice President, General Counsel | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Elizabeth Thompson Executive Vice President, Research and Development | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Aaron Cox Executive Vice President, Chief Financial Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Andy Pasternak Executive Vice President, Chief Strategy Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Paul Hoelscher Former Executive Vice President, Chief Financial Officer Departed during or after this year | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2022
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Aaron L. Cox | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Aaron L. Cox | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Andy Pasternak | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Andy Pasternak | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Elizabeth H.Z. Thompson | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Elizabeth H.Z. Thompson | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Paul W. Hoelscher | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Sean M. Clayton | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Timothy P. Walbert | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Timothy P. Walbert | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2022 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Timothy Walbert | PSU | ◇ | = | — | — |
| RSU | ◇ | = | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Paul Hoelscher | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Andy Pasternak | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Aaron Cox | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | = | — | — | |
| Sean Clayton | RSU | ◇ | ◇ | — | — |
| Elizabeth Thompson | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Aaron Cox
Executive Vice President, Chief Financial Officer · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
Andy Pasternak
Executive Vice President, Chief Strategy Officer · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
Elizabeth Thompson
Executive Vice President, Research and Development · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
Sean Clayton
Executive Vice President, General Counsel · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
Timothy Walbert
Chairman, President and Chief Executive Officer · Employment agreement
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2022
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Michael Grey Lead independent director | ◇ | ◇ | — | — | — | — | ◇ |
William F. Daniel | ◇ | ◇ | — | — | — | ◇ | ◇ |
Susan Mahony, Ph.D | ◇ | ◇ | — | — | — | — | ◇ |
James Shannon, M.D | ◇ | ◇ | — | — | — | — | ◇ |
H. Thomas Watkins | ◇ | ◇ | — | — | — | — | ◇ |
Jeff Himawan, Ph.D | ◇ | ◇ | — | — | — | — | ◇ |
Pascale Witz | ◇ | ◇ | — | — | — | — | ◇ |
Gino Santini | ◇ | ◇ | — | — | — | — | ◇ |
Timothy P. Walbert served on the board in fiscal 2022 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2022
- Alexion Pharmaceuticals, Inc. OLMA
- Alnylam Pharmaceuticals, Inc. ALNY
- Biogen, Inc. BIIB
- BioMarin Pharmaceutical Inc. BMRN
- Exelixis, Inc. EXEL
- Incyte Corporation INCY
- Ionis Pharmaceuticals, Inc. IONS
- Jazz Pharmaceuticals plc JAZZ
- Neurocrine Biosciences, Inc. NBIX
- Regeneron Pharmaceuticals, Inc. REGN
- Seagen, Inc. SGEN
- United Therapeutics Corporation UTHR
- Vertex Pharmaceuticals Inc. VRTX
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Timothy Walbert (Chairman, President and Chief Executive Officer), FY2022 total compensation $20,103,869 (base salary $1,292,727) [exec_comp, SEC accession 0001193125-23-180318, filed 2023-06-30]What this page does not include
Everything above is a fact Horizon Therapeutics Public Ltd disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Horizon Therapeutics Public Ltd sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
175 figures on this page: 172 cited to the filing that reported them, 3 calculated from figures it prints.
172 cited to the filing
3 calculated from the filing
Documents cited
- 0001193125-23-180318Grants of Plan-Based Awards · NON-EMPLOYEE DIRECTOR COMPENSATION · Outstanding Equity Awards at December 31, 2022 · Potential Payments Upon Termination · and 1 more section
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Horizon Therapeutics Public Ltd executive compensation, FY2022.” https://intel.velarion.ai/comp/HZNP (accessed 2026).
Short form: data: Velarion
The Horizon Therapeutics Public Ltd brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Horizon Therapeutics Public Ltd and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Horizon Therapeutics Public Ltd discloses
The companies named in HZNP's own disclosed peer group.
Alexion Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc.Biogen, Inc.BioMarin Pharmaceutical Inc.Exelixis, Inc.Incyte CorporationIonis Pharmaceuticals, Inc.Jazz Pharmaceuticals plcNeurocrine Biosciences, Inc.Regeneron Pharmaceuticals, Inc.Seagen, Inc.United Therapeutics CorporationVertex Pharmaceuticals Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}